Shandong Weigao Group Medical Polymer Company Limited Sustainability Profile
Shandong Weigao Group Medical Polymer Company Limited, commonly referred to as Weigao, is a leading player in the medical device industry, headquartered in Shandong, China. Established in 1988, the company has grown significantly, expanding its operations across various regions, including Asia, Europe, and North America. Weigao specialises in the development and manufacturing of high-quality medical polymer products, including intravenous (IV) products, surgical instruments, and diagnostic devices. Their commitment to innovation and quality has positioned them as a trusted supplier in the healthcare sector. Notably, Weigao has achieved several milestones, including numerous certifications and awards that underscore its dedication to excellence and safety in medical technology. With a strong market presence, Weigao continues to enhance patient care through its advanced medical solutions.
DitchCarbon Score
How does Shandong Weigao Group Medical Polymer Company Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shandong Weigao Group Medical Polymer Company Limited's score of 19 is lower than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shandong Weigao Group Medical Polymer Company Limited's reported carbon emissions
In 2024, Shandong Weigao Group Medical Polymer Company Limited reported total emissions of approximately 126,139,020 kg CO2e, comprising 155,670 kg CO2e from Scope 1 (mobile combustion) and 41,295,430 kg CO2e from purchased steam, alongside 81,747,340 kg CO2e from purchased electricity under Scope 2. The company has not disclosed any Scope 3 emissions data. For the year 2023, emissions data specific to China indicated a total of about 2,978,680 kg CO2e from Scope 1, which included 129,230 kg CO2e from mobile combustion and 19,560 kg CO2e from fugitive emissions. Scope 2 emissions for the same year were reported at approximately 99,528,780 kg CO2e, all from purchased electricity. Despite these figures, Shandong Weigao Group has not set any specific reduction targets or initiatives, nor have they committed to any climate pledges. The company’s emissions intensity for 2023 was reported at about 26,520 tonnes CO2e, reflecting their operational efficiency in relation to revenue. Overall, while Shandong Weigao Group has made strides in emissions reporting, the absence of reduction targets or climate commitments indicates a potential area for future improvement in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2024 | |
|---|---|---|---|
| Scope 1 | 623,070 | 000,000 | 000,000 |
| Scope 2 | - | - | 000,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Shandong Weigao Group Medical Polymer Company Limited's Industry?
How Carbon Intensive is Shandong Weigao Group Medical Polymer Company Limited's Location?
Shandong Weigao Group Medical Polymer Company Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shandong Weigao Group Medical Polymer Company Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
